EVO756 Fails Phase 2b Atopic Dermatitis Trial; Evommune Halts AD Program
EVMN sits 24% above its 52-week low of $10.47.
Summary
Evommune's lead oral candidate EVO756 missed primary and secondary endpoints in a 121-patient Phase 2b atopic dermatitis trial, and the company will not advance it in AD. This is the second failed indication for EVO756 after the June chronic spontaneous urticaria miss, leaving migraine prophylaxis as the only active program for the drug. Management pivots to EVO301, an IL-18BP fusion protein with positive Phase 2a data, but its Phase 2b in AD is not planned until mid-2027. Cash runway extends into 2029, providing a buffer, but the near-term pipeline is now thinner. The stock is likely to reprice sharply on this pivotal data failure, and shares plunged after the company scrapped the eczema drug.
At the time of this announcement, EVMN was trading at $12.96 on NYSE in the Life Sciences sector, with a market capitalization of approximately $474.7M. The 52-week trading range was $10.47 to $33.20. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: BusinessWire.